Fig. 3
The low expression of ADH1A and its association with a worse prognosis in TNBC. (A) Significant reduction of ADH1A mRNA levels in tumor tissues across different stages, as observed in the TCGA database. (B) Marked decrease in ADH1A mRNA levels in various types of breast cancer. (C) Protein levels of ADH1A are lower in tumor tissues at different stages, as indicated by the CPTAC database. (D) ADH1A protein levels in tumor tissues differ across various breast cancer types based on CPTAC data. (E) Kaplan-Meier survival analysis from the TCGA dataset demonstrates the prognostic capacity of ADH1A in TNBC. (F-G) Representative immunohistochemistry images and quantitative assessment of ADH1A expression in TNBC tissues at different stages (Bar = 200 μm). (H) Western blot analysis and quantitative assessment of ADH1A protein levels in six TNBC tissues compared to adjacent normal tissues. **P < 0.01, ***P < 0.001.
